<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00478023</url>
  </required_header>
  <id_info>
    <org_study_id>731200</org_study_id>
    <nct_id>NCT00478023</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain After Abdominal Hysterectomy</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-arm, Placebo- and Comparator- Controlled Trial of the Efficacy and Safety of Multiple Doses of Immediate-release (IR) CG5503 for Postoperative Pain Following Abdominal Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grünenthal GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson Pharmaceutical Research &amp; Development, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grünenthal GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to demonstrate the efficacy and safety of multiple-dose
      application of three different oral doses of CG5503 IR (tapentadol immediate release)
      compared to placebo in women undergoing abdominal hysterectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects undergoing abdominal hysterectomy often experience moderate to severe acute pain
      post-surgery. Normally such pain is controlled when subjects receive repeated doses of opioid
      analgesics. However, opioid therapy is commonly associated with side effects such as nausea,
      vomiting, sedation, constipation, addiction, tolerance, and respiratory depression.
      Tapentadol (CG5503), a newly synthesized drug with an immediate release (IR) formulation,
      also acts as a centrally acting pain reliever but has a dual mode of action. The aim of this
      study is to investigate the effectiveness (level of pain control) and safety (side effects)
      of 3 dose levels of CG5503 IR compared with no drug (placebo) or one dose level of morphine
      (an opioid commonly used to treat post-surgical pain). This study is a randomized,
      double-blind (neither investigator nor patient will know which treatment was received),
      active- and placebo-controlled, parallel-group, multicenter study to evaluate the treatment
      of acute pain after abdominal hysterectomy. The study will include a blinded 72 hour
      in-patient phase immediately following hysterectomy, during which subjects will be treated
      with either 50-, 75-, or 100-mg CG5503 IR, a matched placebo, or 20-mg morphine, and pain
      relief will be periodically assessed. Assessments of pain relief include the pain intensity
      numeric rating scale (PI), pain relief numeric rating scale (PAR), and patient global
      impression of change scale (PGIC). Safety evaluations include monitoring of adverse events,
      physical examinations, and clinical laboratory tests. Venous blood samples will be collected
      for the determination of serum concentrations of CG5503 and morphine. The alternative study
      hypothesis is that at least 1 dose strength of CG5503 will be different from placebo in
      controlling pain at 24 hours (using the mean SPID at 24 hours).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.</measure>
    <time_frame>Baseline to 24 hours after first intake of study drug</time_frame>
    <description>Pain Intensity assessed at predefined time points over a 24 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID24) is from -240 (indicative of an increase in pain) to 240 (indicative of a decrease in pain, assuming patients start with a baseline value of 10 and all subsequent values will be 0).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity</measure>
    <time_frame>Baseline value to 48 hours after first study drug intake.</time_frame>
    <description>Pain Intensity assessed at predefined time points over a 48 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID48) is from -480 (indicative of an increase in pain) to 480 (indicative of a decrease in pain, assuming patients start with a baseline value of 10 and all subsequent values will be 0).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">854</enrollment>
  <condition>Hysterectomy</condition>
  <condition>Postoperative</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tapentadol 50 mg immediate release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tapentadol 75 mg immediate release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Tapentadol 100 mg immediate release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>20 mg IR; 4 - 6 hourly; Total 72 hours</description>
    <arm_group_label>Morphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG5503 IR</intervention_name>
    <description>50mg; 4 - 6 hourly; Total 72 hours</description>
    <arm_group_label>Tapentadol 50 mg immediate release</arm_group_label>
    <other_name>Tapentadol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG5503 IR</intervention_name>
    <description>75mg; 4 -6 hourly; Total 72 hours</description>
    <arm_group_label>Tapentadol 75 mg immediate release</arm_group_label>
    <other_name>Tapentadol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG5503 IR</intervention_name>
    <description>100mg, 4 - 6 hourly; Total 72 hours</description>
    <arm_group_label>Tapentadol 100 mg immediate release</arm_group_label>
    <other_name>Tapentadol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 - 6 hourly; Total 72 hours</description>
    <arm_group_label>Matched placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female between 18 and 80 years of age;

          -  Scheduled to undergo an abdominal hysterectomy with or without bilateral
             salpingo-oophorectomy due to uterine leiomyomas, or dysfunctional uterine bleeding or
             endometrial hyperplasia;

          -  Anesthesiological and surgical procedures performed according to protocol;

          -  Moderate or severe baseline pain following hysterectomy on a Verbal Rating Scale (VRS)
             within 6 hours following the last possible application of morphine subcutaneous;

          -  Pain following hysterectomy of at least 4 on an 11-point Numeric Rating Scale (NRS)
             within 6 hours following the last possible application of morphine subcutaneous;

          -  American Society of Anesthesiologists (ASA) classification I-III.

        Exclusion Criteria:

          -  Vaginal hysterectomy;

          -  Ongoing or known history of painful endometriosis;

          -  Known or suspected chronic pelvic pain syndrome;

          -  Previous abdominal or pelvic open surgery;

          -  History of seizure disorder or epilepsy;

          -  History of alcohol or drug abuse;

          -  Evidence of active infections that may spread to other areas of the body;

          -  severely impaired renal function, moderately or severely impaired hepatic function,

          -  Allergy or hypersensitivity to oxycodone, morphine, fentanyl hydromorphone, heparin,
             or any compound planned to be used during the anesthesia;

          -  Serious complication during surgery and up to randomization;

          -  Pre-operative use within 12hours prior to surgery or peri-operative use of
             non-steroidal anti-inflammatory drugs (NSAIDs);

          -  Treated regularly with opioid analgesic or non-steroidal anti-inflammatory drugs
             (NSAIDs) within 30 days prior to screening;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Rechberger, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samodzielny Publiczny Szpital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 13</name>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 14</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 15</name>
      <address>
        <city>Komarom</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 12</name>
      <address>
        <city>Nylregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 16</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 18</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 23</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 66</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Ruda Slaska</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 21</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 78</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 29</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 31</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 76</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 75</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 61</name>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 71</name>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 37</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 38</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 44</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 73</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 47</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 46</name>
      <address>
        <city>Kragujevac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 70</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 48</name>
      <address>
        <city>Banska Bysterica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 51</name>
      <address>
        <city>Brastislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 52</name>
      <address>
        <city>Brastislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 62</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 50</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 53</name>
      <address>
        <city>Maribor</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 64</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 55</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 56</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 58</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 67</name>
      <address>
        <city>Zaporizhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>Ukraine</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2007</study_first_submitted>
  <study_first_submitted_qc>May 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2007</study_first_posted>
  <results_first_submitted>December 16, 2009</results_first_submitted>
  <results_first_submitted_qc>December 22, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2010</results_first_posted>
  <last_update_submitted>December 20, 2013</last_update_submitted>
  <last_update_submitted_qc>December 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Opioid</keyword>
  <keyword>Central acting analgesic</keyword>
  <keyword>Pain postoperative</keyword>
  <keyword>Abdomen acute</keyword>
  <keyword>CG5503 IR</keyword>
  <keyword>Morphine</keyword>
  <keyword>Placebo</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period for this in-patient, multicenter study occurred between 19 May 2007 and 11 Mar 2008.</recruitment_details>
      <pre_assignment_details>This trial consisted of 5 periods: a Screening (Day –28 to Day -4 to the Pre-operative Visit) a Surgical (Day -1 to 1), a Postoperative Qualification, a Double-blind Treatment(Day 1-4) and a Follow-up Period (4–14 days after the double-blind treatment). The results refer to randomized subjects.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Morphine</title>
          <description>Morphine IR 20mg 4-6 hourly</description>
        </group>
        <group group_id="P2">
          <title>CG5503 50mg</title>
          <description>CG5503 IR 50mg 4 to 6 hourly</description>
        </group>
        <group group_id="P3">
          <title>CG5503 75mg</title>
          <description>CG5503 IR 75mg 4 to 6 hourly</description>
        </group>
        <group group_id="P4">
          <title>CG5503 100mg</title>
          <description>CG5503 IR 100mg 4 to 6 hourly</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Matched Placebo 4 to 6 hourly</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="171"/>
                <participants group_id="P4" count="176"/>
                <participants group_id="P5" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="144"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="146"/>
                <participants group_id="P5" count="114"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of pain, Technical difficulties</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Morphine</title>
          <description>Morphine IR 20mg 4-6 hourly</description>
        </group>
        <group group_id="B2">
          <title>CG5503 50mg</title>
          <description>CG5503 IR 50mg 4 to 6 hourly</description>
        </group>
        <group group_id="B3">
          <title>CG5503 75mg</title>
          <description>CG5503 IR 75mg 4 to 6 hourly</description>
        </group>
        <group group_id="B4">
          <title>CG5503 100mg</title>
          <description>CG5503 IR 100mg 4 to 6 hourly</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Matched Placebo 4 to 6 hourly</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="170"/>
            <count group_id="B2" value="168"/>
            <count group_id="B3" value="171"/>
            <count group_id="B4" value="176"/>
            <count group_id="B5" value="169"/>
            <count group_id="B6" value="854"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="173"/>
                    <measurement group_id="B5" value="166"/>
                    <measurement group_id="B6" value="840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" spread="6.75"/>
                    <measurement group_id="B2" value="47.0" spread="5.56"/>
                    <measurement group_id="B3" value="47.1" spread="5.37"/>
                    <measurement group_id="B4" value="47.5" spread="6.43"/>
                    <measurement group_id="B5" value="47.2" spread="5.83"/>
                    <measurement group_id="B6" value="47.5" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="176"/>
                    <measurement group_id="B5" value="169"/>
                    <measurement group_id="B6" value="854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.</title>
        <description>Pain Intensity assessed at predefined time points over a 24 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID24) is from -240 (indicative of an increase in pain) to 240 (indicative of a decrease in pain, assuming patients start with a baseline value of 10 and all subsequent values will be 0).</description>
        <time_frame>Baseline to 24 hours after first intake of study drug</time_frame>
        <population>Intention to Treat (ITT) and Last Observation Carried Forward (LOCF), i.e. all randomized subjects who received any amount of Investigational Medicinal Product (IMP = study drug) and had a non missing baseline pain assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Morphine</title>
            <description>Morphine IR 20mg 4-6 hourly</description>
          </group>
          <group group_id="O2">
            <title>CG5503 50mg</title>
            <description>CG5503 IR 50mg 4 to 6 hourly</description>
          </group>
          <group group_id="O3">
            <title>CG5503 75mg</title>
            <description>CG5503 IR 75mg 4 to 6 hourly</description>
          </group>
          <group group_id="O4">
            <title>CG5503 100mg</title>
            <description>CG5503 IR 100mg 4 to 6 hourly</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matched Placebo 4 to 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.</title>
          <description>Pain Intensity assessed at predefined time points over a 24 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID24) is from -240 (indicative of an increase in pain) to 240 (indicative of a decrease in pain, assuming patients start with a baseline value of 10 and all subsequent values will be 0).</description>
          <population>Intention to Treat (ITT) and Last Observation Carried Forward (LOCF), i.e. all randomized subjects who received any amount of Investigational Medicinal Product (IMP = study drug) and had a non missing baseline pain assessment.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="172"/>
                <count group_id="O5" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" spread="41.0"/>
                    <measurement group_id="O2" value="49.0" spread="39.87"/>
                    <measurement group_id="O3" value="52.4" spread="41.85"/>
                    <measurement group_id="O4" value="52.9" spread="40.95"/>
                    <measurement group_id="O5" value="29.0" spread="44.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that all CG5503 IR dose groups are equal to the placebo group based on the mean sum of pain intensity difference at 24 hours (SPID24). The alternative hypothesis is that at least one CG5503 IR dose group is different from the placebo group based on the mean SPID24.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted. The Hochberg procedure used for multiplicity comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>18.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>10.9</ci_lower_limit>
            <ci_upper_limit>25.3</ci_upper_limit>
            <estimate_desc>Only pain intensity assessments collected prior to the first dose of any additional analgesic medication considered. Afterwards LOCF used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that all CG5503 IR dose groups are equal to the placebo group based on the mean sum of pain intensity difference at 24 hours (SPID24). The alternative hypothesis is that at least one CG5503 IR dose group is different from the placebo group based on the mean SPID24.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted. The Hochberg procedure used for multiplicity comparisons</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>20.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.7</ci_lower_limit>
            <ci_upper_limit>28.0</ci_upper_limit>
            <estimate_desc>Only pain intensity assessments collected prior to the first dose of any additional analgesic medication considered. Afterwards LOCF used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that all CG5503 IR dose groups are equal to the placebo group based on the mean sum of pain intensity difference at 24 hours (SPID24). The alternative hypothesis is that at least one CG5503 IR dose group is different from the placebo group based on the mean SPID24.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted. The Hochberg procedure used for multiplicity comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>23.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.3</ci_lower_limit>
            <ci_upper_limit>30.4</ci_upper_limit>
            <estimate_desc>Only pain intensity assessments collected prior to the first dose of any additional analgesic medication considered. Afterwards LOCF used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no treatment difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment used.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>20.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.4</ci_lower_limit>
            <ci_upper_limit>27.8</ci_upper_limit>
            <estimate_desc>Only pain intensity assessments collected prior to the first dose of any additional analgesic medication considered. Afterwards LOCF used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity</title>
        <description>Pain Intensity assessed at predefined time points over a 48 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID48) is from -480 (indicative of an increase in pain) to 480 (indicative of a decrease in pain, assuming patients start with a baseline value of 10 and all subsequent values will be 0).</description>
        <time_frame>Baseline value to 48 hours after first study drug intake.</time_frame>
        <population>Intention to treat (ITT) and Last Observation Carried Forward (LOCF), i.e. all randomized subjects who received any amount of Investigational Medicinal Product (IMP = study drug) and had a non missing baseline pain assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Morphine</title>
            <description>Morphine IR 20mg 4-6 hourly</description>
          </group>
          <group group_id="O2">
            <title>CG5503 50mg</title>
            <description>CG5503 IR 50mg 4 to 6 hourly</description>
          </group>
          <group group_id="O3">
            <title>CG5503 75mg</title>
            <description>CG5503 IR 75mg 4 to 6 hourly</description>
          </group>
          <group group_id="O4">
            <title>CG5503 100mg</title>
            <description>CG5503 IR 100mg 4 to 6 hourly</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Matched Placebo 4 to 6 hourly</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity</title>
          <description>Pain Intensity assessed at predefined time points over a 48 hour period using an 11-point Numeric Rating Scale (NRS) where a score of zero indicates &quot;no pain&quot; and a score of ten indicates &quot;pain as bad as you can imagine&quot;. Differences calculated as [baseline-post baseline] at each predefined time point. The theoretical maximum range of Sum of pain intensity differences (SPID48) is from -480 (indicative of an increase in pain) to 480 (indicative of a decrease in pain, assuming patients start with a baseline value of 10 and all subsequent values will be 0).</description>
          <population>Intention to treat (ITT) and Last Observation Carried Forward (LOCF), i.e. all randomized subjects who received any amount of Investigational Medicinal Product (IMP = study drug) and had a non missing baseline pain assessment.</population>
          <units>units on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="163"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="172"/>
                <count group_id="O5" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.6" spread="87.10"/>
                    <measurement group_id="O2" value="112.4" spread="87.32"/>
                    <measurement group_id="O3" value="120.6" spread="87.35"/>
                    <measurement group_id="O4" value="123.5" spread="83.50"/>
                    <measurement group_id="O5" value="71.1" spread="101.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that all CG5503 IR dose groups are equal to the placebo group based on the mean sum of pain intensity difference at 48 hours (SPID48). The alternative hypothesis is that at least one CG5503 IR dose group is different from the placebo group based on the mean SPID48.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted. The Hochberg procedure used for multiplicity comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariate.</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>37.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>21.6</ci_lower_limit>
            <ci_upper_limit>52.6</ci_upper_limit>
            <estimate_desc>Only pain intensity assessments collected prior to the first dose of any additional analgesic medication considered. Afterwards LOCF used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that all CG5503 IR dose groups are equal to the placebo group based on the mean sum of pain intensity difference at 48 hours (SPID48). The alternative hypothesis is that at least one CG5503 IR dose group is different from the placebo group based on the mean SPID48.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted. The Hochberg procedure used for multiplicity comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as covariates.</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>44.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>28.6</ci_lower_limit>
            <ci_upper_limit>59.5</ci_upper_limit>
            <estimate_desc>Only pain intensity assessments collected prior to the first dose of any additional analgesic medication considered. Afterwards LOCF used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that all CG5503 IR dose groups are equal to the placebo group based on the mean sum of pain intensity difference at 48 hours (SPID48). The alternative hypothesis is that at least one CG5503 IR dose group is different from the placebo group based on the mean SPID48.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Adjusted. The Hochberg procedure used for multiplicity comparisons.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least square mean difference</param_type>
            <param_value>51.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>36.1</ci_lower_limit>
            <ci_upper_limit>66.7</ci_upper_limit>
            <estimate_desc>Only pain intensity assessments collected prior to the first dose of any additional analgesic medication considered. Afterwards LOCF used.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no treatment difference.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>No multiplicity adjustment.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and centre as fixed effects and baseline pain as a covariate.</method_desc>
            <param_type>Least square mean difference</param_type>
            <param_value>46.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>31.4</ci_lower_limit>
            <ci_upper_limit>62.4</ci_upper_limit>
            <estimate_desc>Only pain intensity assessments collected prior to the first dose of any additional analgesic medication considered. Afterwards LOCF used.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events are reported.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Morphine</title>
          <description>Morphine IR 20mg 4-6 hourly</description>
        </group>
        <group group_id="E2">
          <title>CG5503 50mg</title>
          <description>CG5503 IR 50mg 4 to 6 hourly</description>
        </group>
        <group group_id="E3">
          <title>CG5503 75mg</title>
          <description>CG5503 IR 75mg 4 to 6 hourly</description>
        </group>
        <group group_id="E4">
          <title>CG5503 100mg</title>
          <description>CG5503 IR 100mg 4 to 6 hourly</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Matched Placebo 4 to 6 hourly</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (10.1)">Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="170"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="106" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="88" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Postoperative anemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="169"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="170"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="169"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Grünenthal GmbH reserves the right to review any publication pertaining to the trial before it is submitted for publication. Neither Grünenthal nor the coordinating Investigator/Investigator has the right to prohibit publication unless publication can be shown to affect possible patent rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Approval to conduct the trial was obtained in Slovenia. No Slovenian subjects were exposed to study drug.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Claudia Leinweber</name_or_title>
      <organization>Grunenthal GmbH</organization>
      <phone>49 241 569 2509</phone>
      <email>claudia.leinweber@grunenthal.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

